Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice.

REASSURE is a global, prospective, non-interventional study to assess long-term safety of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Here we report an interim analysis of patients according to previous use of chemotherapy.

Radium-223 was administered in routine clinical practice. Interim safety analysis was planned after enrolment of the first 600 patients. Patient characteristics and safety data by previous administration of chemotherapy (docetaxel and/or cabazitaxel) were investigated.

This interim analysis included 583 patients. Median duration of observation was 7 months (range, 0-20). Nineteen patients treated with concomitant chemotherapy were excluded, 564 (97%) were eligible for exploratory analysis according to prior use of chemotherapy; 190 (34%) had previously received and completed chemotherapy, and 374 (66%) had not. In the prior versus no prior chemotherapy group, a higher proportion of patients had an Eastern Cooperative Oncology Group performance status of ≥2 (22% vs 11%) and > 20 metastatic lesions (26% vs 15%), median alkaline phosphatase (162.0 vs 115.0 U/L) and prostate-specific antigen (132.0 vs 40.2 ng/mL) levels were higher, and a lower proportion completed 6 radium-223 injections (45% vs 63%). Drug-related treatment-emergent adverse events (TEAEs) occurred in 63 and 48%, and haematological drug-related TEAEs in 21 and 9% of patients who had or had not previously received chemotherapy. Four drug-related deaths were reported, all in the prior chemotherapy group.

The short-term safety profile of radium-223 in routine clinical practice was comparable to other clinical studies, irrespective of prior chemotherapy use. Haematological TEAEs occurred more frequently in the prior chemotherapy group, presumably due to decreased bone marrow function as a consequence of more advanced disease and prior exposure to cytotoxic therapy. Patients who had not previously received chemotherapy appeared to have a lower burden of disease at baseline, and a lower proportion discontinued radium-223 treatment.

European journal of nuclear medicine and molecular imaging. 2019 Jan 12 [Epub]

Sabina Dizdarevic, Peter Meidahl Petersen, Markus Essler, Annibale Versari, Jean-Cyril Bourre, Christian la Fougère, Riccardo Valdagni, Giovanni Paganelli, Samer Ezziddin, Ján Kalinovský, Inga Bayh, Yong Du

Department of Imaging and Nuclear Medicine, Royal Sussex County Hospital, Brighton and Sussex University Hospitals NHS Trust, Eastern Road, Brighton, BN2 5BE, UK. ., Rigshospitalet, Copenhagen, Denmark., Universitätsklinikum Bonn, Bonn, Germany., Azienda Unità Sanitaria Locale - IRCCS di, Reggio Emilia, Italy., Centre Hospitalier Métropole Savoie, Chambery, France., Universitätsklinikum Tübingen, Tübingen, Germany., Università degli Studi di Milano and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy., Universitätsklinikum des Saarlandes, Homburg, Germany., Bayer, Basel, Switzerland., Bayer AG, Wuppertal, Germany., Royal Marsden Hospital, London, UK.